BiotechTube
BioReperia

BioReperia

Uppsala, Sweden· Est.
bioreperia.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

BioReperia leverages its proprietary ZTX® platform, utilizing humanized zebrafish models, to accelerate and improve oncology drug discovery and clinical decision-making. The platform provides rapid, in-vivo data within five days, serving biopharma clients, academia, and healthcare professionals. The company recently underwent a leadership transition, appointing a new CEO with a strong biotech background to drive growth. BioReperia operates as a service and platform provider, generating early revenue through collaborations and research services.

Oncology

Technology Platform

The ZTX® platform utilizes humanized zebrafish in-vivo models to rapidly mimic the complex human tumor microenvironment for drug discovery and precision medicine applications, delivering results within 5 days.

Opportunities

The growing demand for faster, cheaper, and more predictive preclinical models in oncology R&D presents a significant opportunity.
Expansion of the precision medicine ZTX® PREDICT platform into clinical decision support could open a large diagnostic market.
Strategic partnerships or licensing deals with large pharma companies could provide non-dilutive funding and validation.

Risk Factors

Key risks include the need for broader validation of zebrafish models against human clinical outcomes to gain widespread adoption.
Competition from other advanced preclinical models (organoids, murine PDX) and the challenge of changing entrenched industry workflows are significant hurdles.
As a private company, scalability depends on securing ongoing funding or partnership revenue.

Competitive Landscape

BioReperia competes with traditional contract research organizations (CROs) offering murine models, as well as companies developing alternative preclinical platforms like organoids, microphysiological systems, and other in-vivo models. Its differentiation lies in the unique combination of a whole-organism in-vivo model with humanization and a very rapid turnaround time, targeting a specific niche in early-stage oncology discovery and translational research.

More companies in Sweden →